Patent ID: 11913032
Assignee: C3J THERAPEUTICS, INC.
Field: Biotechnology (Chemistry)
Classification: CPC C | IPC C

Claim 14:
15. The method of claim 13, wherein said phage comprises:
i) one or more mutations selected from gp13 C17Y, gp18 D36Y, gp38 D82G and 183S, and gp40 N253D and the phage shows improved host range compared to LUZ19; and/or
ii) a wildtype LUZ19 gp18 replaced with gp18 from virus LKD16; and/or
iii) a deletion of lysine at position 55 of gp34 (gp34L55Δ mutation) and said phage shows increased lytic activity compared to wild type LUZ19.